Form 8-K · Current report
Idexx Laboratories 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000874716
- Accession no.
- 0001104659-26-090033
Summary
IDEXX Laboratories reported second-quarter 2026 revenue of $1,217 million, up 10% as reported, and EPS of $4.27, up 18%, while raising its full-year 2026 revenue and EPS outlook. CEO Mike Erickson attributed the results to innovation across Catalyst, Fecal Dx, and IDEXX inVue Dx platforms and higher diagnostic utilization.
Key points
- IDEXX reported second-quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organic.
- Second-quarter EPS was $4.27, up 18% as reported and 15% on a comparable basis, with operating margin at 35.0%, up 140 basis points as reported.
- CAG Diagnostics recurring revenue grew 11% as reported and 10% organic; IDEXX inVue Dx installed base surpassed 9,000 instruments, with over 1,600 placements during the quarter.
- The company narrowed 2026 revenue guidance to $4,700 million-$4,745 million and raised its 2026 EPS outlook to $14.69-$14.94.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 4, 2026, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.